{
    "clinical_study": {
        "@rank": "117820", 
        "arm_group": {
            "arm_group_label": "Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325", 
            "arm_group_type": "Experimental", 
            "description": "Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days\nCycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose\n      combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive\n      agent."
        }, 
        "brief_title": "Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IND Number: 79,599 and 101,943\n\n      Other: Phase 1 Clinical Pharmacology drug interaction study in healthy female subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy females within age of 18-40 years\n\n          -  Must be a Women of Childbearing potential\n\n          -  Must be on a stable regimen of oral contraceptive therapy for at least 3 consecutive\n             months prior to study start\n\n        Exclusion Criteria:\n\n          -  Subjects must  not have any significant acute or chronic medical illnesses or\n             conditions precluding safe use of oral contraceptives\n\n          -  Prior exposure to DCV, ASV or BMS-791325 within 30 days of dosing on study day 1\n\n          -  Smoking within 6 months of study start"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103569", 
            "org_study_id": "AI443-016"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "FDC of Daclatasvir, Asunaprevir and BMS-791325", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "FDC of Norethindrone and Ethinyl Estradiol", 
                "intervention_type": "Drug", 
                "other_name": "Loestrin\u00ae"
            }, 
            {
                "arm_group_label": "Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Norethindrone", 
                "Norethindrone acetate", 
                "Norinyl", 
                "Ethynylestradiol mixture with norethindrone", 
                "Contraceptives, Oral, Combined", 
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 1, 2014", 
        "number_of_arms": "1", 
        "official_title": "Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone", 
                "safety_issue": "No", 
                "time_frame": "Day 21 to Day 49"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone", 
                "safety_issue": "No", 
                "time_frame": "Day 21 to Day 49"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dose-normalized area under the concentration versus time curve in 1 dosing interval (AUC (TAU)) of Ethinyl Estradiol and Norethindrone", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Dose-normalized maximum observed plasma concentration (Cmax) of Ethinyl Estradiol and Norethindrone", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Ethinyl Estradiol and Norethindrone", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Safety measured by occurrence of Adverse events (AEs), serious AEs and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Safety measured by abnormalities in vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Safety measured by findings on Electrocardiogram (ECG) measurements and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 50"
            }, 
            {
                "measure": "Safety measured by marked abnormalities in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 50"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}